Exifone

Summary

Exifone (CHEMBL329522) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 278.21 Da · C13H10O7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL329522
Name	Exifone
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	40399
Molecular formula	C13H10O7
Molecular weight	278.21
InChIKey	XEDWWPGWIXPVRQ-UHFFFAOYSA-N

SMILES: C1=CC(=C(C(=C1C(=O)C2=CC(=C(C(=C2)O)O)O)O)O)O

IUPAC name: (2,3,4-trihydroxyphenyl)-(3,4,5-trihydroxyphenyl)methanone

Also known as: Exifona, Exifone, NSC-680919, exifone, EXIFONE, SID144213864, SID144208648, SID170466234

Patent coverage: 580 distinct patent families (1,547 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 1,510 (98%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Histone deacetylase 1, Replicase polyprotein 1ab.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HDAC1	7.35	EC50	45	nM	CHEMBL_ACT_25671370
P0DTD1	5.36	IC50	4380	nM	CHEMBL_ACT_19964295

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).